文献速递妇科肿瘤

MITO-8研究:部分铂敏感复发卵巢癌铂类与非铂类化疗的生活质量分析

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

MITO-8研究将部分铂敏感复发卵巢癌患者随机分配至铂类或非铂类化疗,生活质量为次要终点。结果显示非铂类组情绪功能、总体健康状况/生活质量、疲乏和呼吸困难恶化更明显,而铂类组其他化疗副作用更差;铂类组无进展生存期和客观缓解率显著更优。

要点

  • 非铂类化疗在情绪功能、总体健康、疲乏和呼吸困难方面恶化更明显。
  • 铂类化疗组其他化疗副作用更差,但情绪功能和疼痛改善更频繁。
  • 铂类组无进展生存期和客观缓解率显著优于非铂类组。

核心结论

  • 部分铂敏感复发卵巢癌患者中,铂类化疗虽毒性相关条目更差,但部分功能和症状恶化程度低于非铂类化疗。

研究设计与样本

  • 随机对照研究,纳入215例铂类化疗后6-12个月复发或进展的卵巢癌患者,随机接受铂类或非铂类化疗。
  • 生活质量采用EORTC C-30和OV-28问卷在基线、第3和第6周期评估,所有分析基于意向治疗。

主要发现

  • 151例(70.2%)完成基线问卷,两组均衡;此后非铂类组缺失率更高。
  • 平均变化分析中,C30量表中非铂类组情绪功能、总体健康状况/生活质量、疲乏和呼吸困难显著更差,效应量0.30至0.51。
  • OV28量表中其他化疗副作用条目在铂类组第3和第6周期显著更差,效应量分别为0.70和0.54。
  • 最佳反应分析中,铂类组情绪功能和疼痛改善及周围神经病变和其他化疗副作用恶化显著更频繁。
  • 铂类组无进展生存期(中位9个月 vs 5个月,P=0.001)和客观缓解率(51.6% vs 19.4%,P=0.0001)显著更优。

临床怎么用

  • 对于部分铂敏感复发卵巢癌,选择铂类化疗时需权衡其疗效优势与毒性相关生活质量恶化。
  • 非铂类化疗虽部分毒性较低,但情绪功能、总体健康和疲乏等恶化更明显,需关注患者报告结局。

局限性

  • 非铂类组问卷缺失率更高,可能影响生活质量分析结果的解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MITO-8 showed that prolonging platinum-free interval by introducing non-platinum-based chemotherapy (NPBC) does not improve prognosis of patients with partially platinum-sensitive recurrent ovarian cancer. Quality of life (QoL) was a secondary outcome. PATIENTS AND METHODS: Ovarian cancer patients recurring or progressing 6-12 months after previous platinum-based chemotherapy (PBC) were randomized to receive PBC or NPBC as first treatment. QoL was assessed at baseline, third and sixth cycles, with the EORTC C-30 and OV-28 questionnaires. Mean changes and best response were analysed. Progression-free survival, response rate, and toxicity are also reported for proper interpretation of data. All analyses were based on intention-to-treat. RESULTS: Out of the 215 patients, 151 (70.2%) completed baseline questionnaire, balanced between the arms; thereafter, missing rate was higher in the NPBC arm. At mean change analysis, C30 scores were prevalently worse in the NPBC than PBC arm, statistical significance being attained for emotional functioning, global health status/QoL, fatigue, and dyspnoea (effect sizes ranging from 0.30 to 0.51). Conversely, as for OV28 scale, the other chemotherapy side-effects item was significantly worse with PBC at three and six cycles, with a larger effect size (0.70 and 0.54, respectively). At best response analysis, improvement of emotional functioning and pain and worsening of peripheral neuropathy and other chemotherapy side-effects were significantly more frequent in the PBC arm. Progression-free survival (median 9 versus 5 months, P = 0.001) and objective response rate (51.6% versus 19.4%, P = 0.0001) were significantly better with PBC. Allergy, blood cell count, alopecia, nausea, musculoskeletal, and neurological side-effects were more frequent and severe with PBC; hand-foot skin reaction, rash/desquamation, mucositis, and vascular events were more frequent with NPBC. CONCLUSION: MITO-8 QoL analysis shows that deterioration of some functioning and symptom scales is lower with PBC, with improvement of emotional functioning and pain, despite worsening of toxicity-related items. CLINICALTRIALS.GOV: NCT00657878.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Piccirillo MC, Scambia G, Bologna A, et al. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. Ann Oncol. 2018. PMID: 29462248. doi:10.1093/annonc/mdy062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。